CTLA4 and melanoma: Profound responses have been seen in patients with melanoma and non-small cell lung carcinoma (NSCLC) using therapies targeting the programmed death (ligand)-1 (PD[L]-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) signaling pathways [77].